Company intelligence / Profile preview

Nanjing Ruinian Best Pharmaceutical

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Nanjing Ruinian Best Pharmaceutical is a Chinese pharmaceutical manufacturer specializing in development and large‑scale commercial production of solid and liquid dosage forms (including sterile unit doses) for human medicines; it operates as a contract manufacturer and was acquired by Unither Pharmaceuticals to expand Unither’s global CDMO footprint.

Modalities: Small molecule
Industry: Contract Manufacturing Organization

Partnerships

Acquisition/strategic integration with Unither Pharmaceuticals, through which NRB serves as Unither’s manufacturing base in China for solid, liquid and sterile unit‑dose products.

Beyond the preview

Go deeper on Nanjing Ruinian Best Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Ruinian Best Pharmaceutical.

Explore the full profile